The concept of FDG-PET endophenotype in Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and conceptual analysis with no primary human data or systematic synthesis
PubMed 21630036 · doi:10.1007/s10072-011-0633-1
What was done
This narrative review analyzed the theoretical construct of the "endophenotype" in late-onset Alzheimer's disease (LOAD). The authors evaluated published literature examining [18F]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) patterns in asymptomatic carriers of the ApoE epsilon-4 allele and children of mothers with AD, discussing its pathophysiological significance, positive predictive accuracy, and utility in identifying risk and protective factors.
What was found
The abstract provides no quantitative metrics, effect sizes, or specific diagnostic accuracy values. It reports qualitatively that FDG-PET demonstrates a characteristic pattern of hypometabolism in AD-related brain regions in asymptomatic ApoE epsilon-4 carriers and maternal descendants of AD patients. The authors conclude conceptually that the term "endophenotype" should be restricted to investigating promoting and protective risk factors rather than applied as a tool for preclinical diagnosis of LOAD.
Why it matters
It clarifies the conceptual boundaries of neuroimaging biomarkers in Alzheimer's disease, distinguishing between endophenotypes suited for genetic/etiological risk modeling and validated biomarkers required for individual preclinical diagnosis.
Limits
The paper is a non-systematic narrative review providing theoretical synthesis without original empirical data or quantitative meta-analysis. No sample sizes, effect magnitudes, or statistical validation parameters are reported in the abstract.
Cited by
- supports Radionuclide-labeled glucose imaging can detect regional brain glucose hypometabolism and predict Alzheimer's disease 10 years in advance.